Axonal loss in the pathology of MS: Consequences for understanding the progressive phase of the disease

Journal of the Neurological Sciences

Volumn 206, Issue 2, 2003, Pages 165-171

  Bjartmar, C ^a   Wujek, J R ^a   Trapp, B D ^a  

^a LERNER RESEARCH INSTITUTE   (United States)

Author keywords

Axon; Disability; Multiple sclerosis; Pathology; Transection

Indexed keywords

6 NITRO 7 SULFAMOYLBENZO[F]QUINOXALINE 2,3 DIONE; MYELIN;

ALLERGIC ENCEPHALOMYELITIS; AXONAL INJURY; CENTRAL NERVOUS SYSTEM; CERVICAL SPINAL CORD; CORRELATION ANALYSIS; DEMYELINATION; DISEASE COURSE; DISEASE MODEL; EFFERENT NERVE; GRAY MATTER; HUMAN; INFLAMMATORY DISEASE; MULTIPLE SCLEROSIS; NERVE DEGENERATION; NERVE FIBER DEGENERATION; NEUROLOGIC DISEASE; NEUROPROTECTION; NONHUMAN; NUCLEAR MAGNETIC RESONANCE IMAGING; ONSET AGE; PATHOLOGY; PATIENT MONITORING; PRIORITY JOURNAL; RELAPSE; REMISSION; REVIEW; SPINAL CORD; SPINAL CORD LESION; WHITE MATTER;

EID: 0037441487     PISSN: 0022510X     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0022-510X(02)00069-2     Document Type: Article

References (51)

1. Lassmann H. Neuropathology in multiple sclerosis: new concepts. Mult. Scler. 4:1998;93-98.
2. Trapp B.D., Bö L., Mörk S., Chang A. Pathogenesis of tissue injury in MS lesions. J. Neuroimmunol. 98:1999;49-56.
3. Noseworthy J.H., Lucchinetti C., Rodriguez M., Weinshenker B.G. Multiple sclerosis. N. Engl. J. Med. 343:2000;938-952.
4. Charcot M. Histologie de le sclerose en plaques. Gaz. Hop. 141:1868;554-558.
5. Kornek B., Lassmann H. Axonal pathology in multiple sclerosis: a historical note. Brain Pathol. 9:1999;651-656.
6. Ferguson B., Matyszak M.K., Esiri M.M., Perry V.H. Axonal damage in acute multiple sclerosis lesions. Brain. 120:1997;393-399.
7. Trapp B.D., Peterson J., Ransohoff R.M.et al. Axonal transection in the lesions of multiple sclerosis. N. Engl. J. Med. 338:1998;278-285.
8. Kornek B., Storch M.K., Weissert R.et al. Multiple sclerosis and chronic autoimmune encephalomyelitis. A comparative quantitative study of axonal injury in active, inactive, and remyelinated lesions. Am. J. Pathol. 157:2000;267-276.
9. Lu F., Selak M., O'Connor J.et al. Oxidative damage to mitochondrial DNA and activity of mitochondrial enzymes in chronic active lesions of multiple sclerosis. J. Neurol. Sci. 177:2000;95-103.
10. Pitt D., Werner P., Raine C.S. Glutamate excitotoxicity in a model of multiple sclerosis. Nat. Med. 6:2000;67-70.
11. + T cells dominate the T cell infiltrate in active multiple sclerosis lesions as shown by micromanipulation and single cell polymerase chain reaction. J. Exp. Med. 192:2000;393-404.
12. + T cells in a model for multiple sclerosis. J. Exp. Med. 194:2001;669-676.
13. Medana I., Martinic M.A., Wekerle H., Neumann H. Transection of major histocompatibility complex class I-induced neurites by cytotoxic T lymphocytes. Am. J. Pathol. 159:2001;809-815.
14. Smith K.J., Kapoor R., Hall S.M., Davies M. Electrically active axons degenerate when exposed to nitric oxide. Ann. Neurol. 49:2001;470-476.
15. Shi R., Blight A.R. Compression injury of mammalian spinal cord in vitro and the dynamics of action potential conduction failure. J. Neurophysiol. 76:1996;1572-1580.
16. Wujek J.R., Bjartmar C., Richer E.et al. Axon loss in the spinal cord determines permanent neurological disability in an animal model of multiple sclerosis. J. Neuropathol. Exp. Neurol. 61:2002;23-32.
17. Ganter P., Prince C., Esiri M.M. Spinal cord axonal loss in multiple sclerosis: a post-mortem study. Neuropathol. Appl. Neurobiol. 25:1999;459-467.
18. Lovas G., Szilagyi N., Majtenyi K.et al. Axonal changes in chronic demyelinated cervical spinal cord plaques. Brain. 123:2000;308-317.
19. Evangelou N., Esiri M.M., Smith S.et al. Quantitative pathological evidence for axonal loss in normal appearing white matter in multiple sclerosis. Ann. Neurol. 47:2000;391-395.
20. Bjartmar C., Kinkel R.P., Kidd G.et al. Axonal loss in normal-appearing white matter in a patient with acute MS. Neurology. 57:2001;1248-1252.
21. Simon J.H., Kinkel R.P., Jacobs L.et al. A Wallerian degeneration pattern in patients at risk for MS. Neurology. 54:2000;1155-1160.
22. Bjartmar C., Kidd G., Mörk S.et al. Neurological disability correlates with spinal cord axonal loss and reduced N-acetyl aspartate in chronic multiple sclerosis patients. Ann. Neurol. 48:2000;893-901.
23. Coles A.J., Wing M.G., Molyneux P.et al. Monoclonal antibody treatment exposes three mechanisms underlying the clinical course of multiple sclerosis. Ann. Neurol. 46:1999;296-304.
24. Rudick R.A., Goodman A., Herndon R.M., Panitch H.S. Selecting relapsing remitting multiple sclerosis patients for treatment: the case for early treatment. J. Neuroimmunol. 98:1999;22-28.
25. Bjartmar C., Yin X., Trapp B.D. Axonal pathology in myelin disorders. J. Neurocytol. 28:1999;383-395.
26. Scherer S. Axonal pathology in demyelinating diseases. Ann. Neurol. 45:1999;6-7.
27. Yin X., Crawford T.O., Griffin J.W.et al. Myelin-associated glycoprotein is a myelin signal that modulates the caliber of myelinated axons. J. Neurosci. 18:1998;1953-1962.
28. Griffiths I., Klugmann M., Anderson T.et al. Axonal swellings and degeneration in mice lacking the major proteolipid of myelin. Science. 280:1998;1610-1613.
29. Waxman S.G. Acquired channelopathies in nerve injury and MS. Neurology. 56:2001;1621-1627.
30. Waxman S.G. Demyelinating diseases - new pathological insights, new therapeutic targets. N. Engl. J. Med. 338:1998;223-225.
31. Bjartmar C., Trapp B.D. Axonal and neuronal degeneration in multiple sclerosis: mechanisms and functional consequences. Curr. Opin. Neurol. 14:2001;271-278.
32. Reddy H., Narayanan S., Arnoutelis R.et al. Evidence for adaptive functional changes in the cerebral cortex with axonal injury from multiple sclerosis. Brain. 123:2000;2314-2320.
33. Gonen O., Catalaa I., Babb J.S.et al. Total brain N-acetylaspartate: a new measure of disease load in MS. Neurology. 54:2000;15-19.
34. De Stefano N., Matthews P.M., Fu L.et al. Axonal damage correlates with disability in patients with relapsing-remitting multiple sclerosis. Results of a longitudinal magnetic resonance spectroscopy study. Brain. 121:1998;1469-1477.
35. Fu L., Matthews P.M., De Stefano N. Imaging axonal damage of normal-appearing white matter in multiple sclerosis. Brain. 121:1998;103-113.
36. Matthews P.M., De Stefano N., Narayanan S.et al. Putting magnetic resonance spectroscopy studies in context: axonal damage and disability in multiple sclerosis. Semin. Neurol. 18:1998;327-336.
37. Trapp B.D., Ransohoff R.M., Fisher E., Rudick R.A. Neurodegeneration in multiple sclerosis: relationship to neurological disability. Neuroscientist. 5:1999;48-57.
38. Lloyd K.G. CNS compensation to dopamine neuron loss in Parkinson's disease. Adv. Exp. Med. Biol. 90:1977;255-266.
39. Bradley W.G. Recent views on amyotrophic lateral sclerosis with emphasis on electrophysiological studies. Muscle Nerve. 10:1987;490-502.
40. Yu M., Nishiyama A., Trapp B.D., Tuohy V. Interferon-β inhibits progression of relapsing-remitting experimental autoimmune encephalomyelitis. J. Neuroimmunol. 64:1996;91-100.
41. Altin J.G., Sloan E.K. The role of CD45 and CD45-associated molecules in T cell activation. Immunol. Cell Biol. 75:1997;430-445.
42. Confavreux C., Vukusic S., Moreau T., Adeleine P. Relapses and progression of disability in multiple sclerosis. N. Engl. J. Med. 343:2000;1430-1438.
43. Brownell B., Hughes J.T. The distribution of plaques in the cerebrum in multiple sclerosis. J. Neurol. Neurosurg. Psychiatry. 25:1962;315-320.
44. Lumsden C.E. The neuropathology of multiple sclerosis. Vinken P.J., Bruyn G.W. Handb. Clin. Neurol. vol. 9:1970;217-309 North-Holland, Amsterdam.
45. Kidd D., Barkhof F., McConnell R.et al. Cortical lesions in multiple sclerosis. Brain. 122:1999;17-26.
46. Peterson J.W., Bö L., Mörk S.et al. Transected neurites, apoptotic neurons, and reduced inflammation in cortical multiple sclerosis lesions. Ann. Neurol. 50:2001;389-400.
47. Sharma R., Narayana P.A., Wolinsky J.S. Grey matter abnormalities in multiple sclerosis: proton magnetic resonance spectroscopic imaging. Mult. Scler. 7:2001;221-226.
48. Filippi M. Multiple sclerosis: a white matter disease with associated gray matter damage. J. Neurol. Sci. 185:2001;3-4.
49. Rao S.M., Leo G.J., Bernardin L., Unverzagt F. Cognitive dysfunction in multiple sclerosis: I. Frequency, patterns, and prediction. Neurology. 41:1991;685-691.
50. Beatty W.W., Paul R.H., Wilbanks S.L.et al. Identifying multiple sclerosis patients with mild or global cognitive impairment using the Screening Examination for Cognitive Impairment (SEFCI). Neurology. 45:1995;718-723.
51. Blinkenberg M., Rune K., Jensen C.V.et al. Cortical cerebral metabolism correlates with MRI lesion load and cognitive dysfunction in MS. Neurology. 54:2000;558-564.